Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRIKE: Pembrolizumab and Tivozanib for High-Risk Renal Cell Carcinoma
NCT06661720Phase 3Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Mar 2025
- Primary completion
- Nov 2037
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tivozanib in renal cell carcinoma (RCC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Disease-Free Survival at 10 years. Started Mar 2025; status: recruiting.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06661720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06661720.